Give women the support they need on their journey with vaginal atrophy

Women may want their healthcare professional to take the lead when talking about vaginal atrophy, even though understanding the condition is important to them.1

Blissel 50 micrograms/g vaginal gel is licensed for the treatment of symptoms of vaginal atrophy due to estrogen deficiency in postmenopausal women. Please refer to Summary of Product Characteristics (SmPC) before prescribing.

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

NEW VIDEOS
CLICK TO PLAY

“Why does talking about GSM/VVA really matter?”

Prescribing and adverse event reporting information can be found at the end of this video.

The diagnosis of vaginal atrophy is not always straightforward

Earlier diagnosis might help stop some of the progressive changes that can occur with vaginal atrophy, and support women’s quality of life.2-4

“How can we break through some of the stigma surrounding GSM/VVA?”

Prescribing and adverse event reporting information can be found at the end of this video.

Vaginal atrophy can present in a number of different ways, including vaginal dryness, dysuria, itching, burning, and pain during sex.5

“How to explain GSM/VVA treatments to patients”

Prescribing and adverse event reporting information can be found at the end of this video.

There are many reasons why women may hesitate to discuss the symptoms of vaginal atrophy.6

These could include believing that nothing can be done, feelings of discomfort, or concerns that the topic is inappropriate to raise.6

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

Order your FREE demonstration pack:

Please click here to order your FREE Blissel®(estriol50micrograms/g) VAGINAL GEL
placebo demonstration pack.
The kit contains:

  • Applicator
  • Placebogel
  • QR code links for access to Blissel® Summary of Product Characteristics and Patient Information Leaflets.
Click here to order

Upcoming Webinars 2026

Our next FREE ONLINE
Webinar is on the 30th June 2026
between 7.30pm – 9.30pm

Click here to find out more

My Blissel® Time to talk
Video Library

In depth discussions around various issues arising when treating the menopause with Dr Julie Oliver, Dr Michelle Olver, Dr Radhika Vohra, Dr Anne Connolly, Dr Diana Mansour and Nurse Consultant Nikki Noble.

Click here to open and play the videos

Ultra low dose estriol vaginal gel7,8

1. Krychman M, et al. J Sex Med 2017;14:425-433. 2. Moral E, et al. Menopause. 2018;25(12):1418-23. 3. Cagnacci A, et al. Climacteric. 2019;22(1):85-89. 4. NAMS position statement. Menopause. 2020;27(9):976-92. 5. Palma F, et al. Maturitas. 2018;108:18–23. 6. Kagan R, et al. Drugs Aging. 2019;36:897–908. 7. Cano A, et al. Menopause. 2012;19(10):1130-9. 8. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Date of preparation: May 2026 | UK-BLS-668a

BlisselⓇ (Estriol 50 Micrograms/G Vaginal Gel)
Safety Information:

CLOSE X


  • For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • BlisselⓇ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
  • Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.1

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Common (≥1/100 to <1/10) and (≥1/1000 to <1/100) undesirable effects1


Date of preparation: April 2026 Item code: UK-BLS-671(1)